Gonzalez I.,Institute Acustica |
Fernandez L.J.,IKERLAN - IK4 |
Gomez T.E.,Institute Acustica |
Berganzo J.,IKERLAN - IK4 |
And 2 more authors.
Sensors and Actuators, B: Chemical | Year: 2010
A new polymer microchip is presented in this paper for separation and particle sorting in flowing suspensions. It includes a microchannel where a fluid-sample containing particles flows in parallel with another liquid. The working principle is based on an ultrasonic actuation on the cross-section of the chip, which behaves as a multilayer system. That part of the wave established within the channel includes a node of pressure strategically located within the collector fluid path, where the target particles collected to be extracted from their host sample. The use of a polymer as the constitutive material of the chip, new in this type of devices, allows a channel width somewhat larger than a quarter of a wavelength, which does not fit any of the conventional models but it represents an intermediate situation. The device has been fabricated by standard SU-8 photolithography using PMMA as substrate. In the experiments, polystyrene particles of 20 μm in diameter have been extracted from aqueous suspensions containing 6-μm sized particles by a strategic application of ultrasonic waves. A high efficiency of particle separation, over 95%, at different concentrations and flow rates, prove the feasibility of the device to carry out sorting processes on flowing suspensions. © 2009 Elsevier B.V. All rights reserved. Source
Cuatrecasas G.,Centro Medico Teknon |
Alegre C.,Institute Universitari Dexeus |
Fernandez-Sola J.,University of Barcelona |
Gonzalez M.J.,Institute Universitari Dexeus |
And 15 more authors.
Pain | Year: 2012
Functional defects in growth hormone (GH) secretion and its efficacy as a complementary treatment have been suggested for fibromyalgia. This study investigated the efficacy and safety of low-dose GH as an add-on therapy in patients with both severe FM and low insulin-like growth factor 1 levels. A total of 120 patients were enrolled in a multicenter, placebo-controlled study for 18 months. They were randomly assigned to receive either 0.006 mg/kg/day of GH subcutaneously (group A, n = 60) or placebo (group B, n = 60) for 6 months (blind phase). The placebo arm was switched to GH treatment from month 6 to month 12 (open phase), and a follow-up period after GH discontinuation was performed until month 18. Standard treatment for fibromyalgia (selective serotonin re-uptake inhibitors, opioids, and amitriptyline) was maintained throughout the study. Number and intensity of tender points, Fibromyalgia Impact Questionnaire (FIQ) with its subscales, and EuroQol 5 dimensions test (EQ5D) with visual analogue scale (VAS) were assessed at different time points. At the end of the study, 53% of group A patients obtained fewer than 11 positive tender points, vs 33% of group B patients (P < .05). 39.1% vs 22.4% reached more than 50% improvement in VAS (P < .05). Group A patients showed significantly improved FIQ scores (P = .01) compared with group B. Although GH discontinuation worsened all scores in both groups during follow-up, impairment in pain perception was less pronounced in the GH-treated group (P = .05). In this largest and longest placebo-controlled trial performed in FM (NCT00933686), addition of GH to the standard treatment is effective in reducing pain, showing sustained action over time. © 2012 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved. Source